Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01665794
Recruitment Status : Recruiting
First Posted : August 15, 2012
Last Update Posted : April 29, 2019
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Multiple Myeloma Research Foundation
Information provided by (Responsible Party):
University of Chicago

Tracking Information
First Submitted Date  ICMJE August 13, 2012
First Posted Date  ICMJE August 15, 2012
Last Update Posted Date April 29, 2019
Actual Study Start Date  ICMJE August 13, 2012
Estimated Primary Completion Date November 1, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 30, 2018)
  • Maximum tolerated dose (MTD) of carfilzomib when administered in combination with pomalidomide and dexamethasone [ Time Frame: 28 days ]
  • Partial response rate after 4 courses according to International Myeloma Working Group (IMWG) criteria [ Time Frame: 4 months ]
    The proportion and exact 95% binomial confidence interval for the response rate will be reported adjusted for the two-stage design of this trial.
  • Response rates of carfilzomib, pomalidomide, dexamethasone, and daratumumab dosing according to International Myeloma Working Group (IMWG) criteria [ Time Frame: 4 months ]
Original Primary Outcome Measures  ICMJE
 (submitted: August 14, 2012)
  • MTD of carfilzomib when administered in combination with fixed dosing pomalidomide and dexamethasone [ Time Frame: 28 days ]
  • Partial response rate after 4 courses according to IMW criteria [ Time Frame: 4 months ]
    The proportion and exact 95% binomial confidence interval for the response rate will be reported adjusted for the two-stage design of this trial.
Change History Complete list of historical versions of study NCT01665794 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: August 14, 2012)
  • Overall response rate [ Time Frame: Up to 2 years ]
    Defined as at least a partial response to therapy, will be reported along with its exact 95% binomial confidence
  • Time to progression [ Time Frame: Up to 2 years ]
    Estimated using the product-limit method of Kaplan and Meier.
  • Duration of response [ Time Frame: From the date of the clinical examination which confirmed the response, until the date of disease progression, or censoring at the date of last clinical follow-up up to 2 years ]
    Assessed conditional upon achieving at least a partial response.
  • Progression-free survival [ Time Frame: From the date of first therapy until the date of documented disease progression or death up to 2 years ]
    Estimated using the product-limit method of Kaplan and Meier.
  • Overall survival [ Time Frame: Up to 2 years ]
    Estimated using the product-limit method of Kaplan and Meier.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Official Title  ICMJE Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma
Brief Summary

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete.

This study will also investigate the effects of adding daratumumab to the combination of carfilzomib, pomalidomide and dexamethasone.

Detailed Description Patients receive carfilzomib, pomalidomide, and dexamethasone in 28 days treatment cycles. Study treatment continues for as long a their myeloma does not worsen and they do not have unacceptable side effects. After completion of study treatment, patients are followed for up to 2 years.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Multiple Myeloma
Intervention  ICMJE
  • Drug: Pomalidomide
    Pomalidomide taken orally at assigned dose.
    Other Names:
    • CC-4047
    • Pomalyst(R)
  • Drug: Carfilzomib
    Carfilzomib given by intravenous (IV) infusion at assigned dose.
    Other Names:
    • Kyprolis (R)
    • PR-171
  • Drug: dexamethasone
    Dexamethasone taken orally of given by IV infusion.
    Other Names:
    • Aeroseb-Dex
    • Decaderm
    • Decadron
    • DM
    • DXM
  • Drug: Daratumumab
    Daratumumab given by intravenous (IV) infusion at assigned dose.
    Other Name: Daralex
Study Arms  ICMJE
  • Experimental: PdC Group
    Patients receive carfilzomib, pomalidomide, and dexamethasone at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: Pomalidomide
    • Drug: Carfilzomib
    • Drug: dexamethasone
  • Experimental: PdC + Dara Group
    Patients receive carfilzomib, pomalidomide, dexamethasone, and daratumumab at indicated doses and schedule every 28 days. Patients may continue to receive treatment in the absence of disease progression or unacceptable toxicity.
    Interventions:
    • Drug: Pomalidomide
    • Drug: Carfilzomib
    • Drug: dexamethasone
    • Drug: Daratumumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 30, 2018)
101
Original Estimated Enrollment  ICMJE
 (submitted: August 14, 2012)
92
Estimated Study Completion Date  ICMJE November 1, 2022
Estimated Primary Completion Date November 1, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Relapsed and relapsed/refractory multiple myeloma requiring systemic therapy
  • Failed at least one prior treatment for multiple myeloma (must have received lenalidomide)

    • To be enrolled as second line therapy: Must be refractory to lenalidomide (progression on therapy or within 60 days of lenalidomide dosing)
  • Measurable disease, as indicated by one or more of the following:

    • Serum M-protein >= 0.5 g/dL
    • Urine M-protein >= 200 mg/24 hours
    • If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative immunoglobulin levels are acceptable
    • Involved serum free light chains ≥ 10 mg/dL (free light change ratio must be abnormal)
  • Aged 18 years or older
  • Life expectancy of more than 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Adequate Liver Function

    • Bilirubin < 1.5 times the upper limit of normal (ULN)
    • Aspartate aminotransferase (AST) < 2.5 times ULN
    • Alanine aminotransferase (ALT) < 2.5 times ULN
  • Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
  • Hemoglobin >= 8 g/dL
  • Platelet count >= 75 x 10^9/L (should be independent of platelet transfusions for at least 2 weeks)
  • Calculated or measured creatinine clearance of >= 30 mL/minute
  • Written informed consent
  • Negative pregnancy test (for women of childbearing potential) within 10-14 days of starting study treatment and again within 24 hours of first pomalidomide dose
  • Must agree to practice abstinence or use two acceptable methods of birth control
  • Men must agree to use latex condom during sexual contact with women of childbearing potential (even if post vasectomy)
  • Must agree to adhere to all study requirements, visit schedule, outpatient treatment, required concomitant medications, and laboratory monitoring
  • Must register to mandatory POMALYST REMS™ program and be willing and able to comply with the requirements of the POMALYST REMS™ program

Exclusion Criteria:

  • Patients for whom there is the prospect of stem cell transplantation in the next 6 months in the treatment plan are excluded
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
  • Plasma cell leukemia
  • Waldenström's macroglobulinemia or immunoglobulin M (IgM) myeloma
  • Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)
  • Participation in an investigational therapeutic study within 3 weeks or within 5 drug half lives (t1/2) prior to first dose, whichever time is greater
  • Patients known to be refractory to any proteasome inhibitor other than bortezomib or carfilzomib
  • Pregnant or lactating
  • History of allergy to mannitol or prior hypersensitivity to thalidomide, lenalidomide or pomalidomide
  • Major surgery within 3 weeks prior to first dose,
  • Prior peripheral stem cell transplant within 12 weeks of study enrollment
  • Has received any anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal (with the exception of hormones for thyroid conditions or estrogen replacement therapy [ERT]), or any investigational therapy within 21 days of enrollment
  • Myocardial infarction within 6 months prior to enrollment, New York Heart Associate (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  • Uncontrolled hypertension or diabetes
  • Acute active infection requiring systemic antibiotics, antivirals, or anti fungals within two weeks prior to first dose
  • Known or suspected human immunodeficiency (HIV) infection, known HIV seropositivity
  • Active hepatitis A, B, or C infection
  • Non-hematologic malignancy within the past 3 years except adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix or breast, prostate cancer < Gleason grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone
  • Any clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent
  • Significant neuropathy (grades 3-4, or grade 2 with pain) at the time of the first dose and/or within 14 days before enrollment
  • Contraindications to any of the required concomitant drugs, including proton-pump inhibitor (eg, lansoprazole), enteric-coated aspirin, allopurinol or if a history of prior thrombotic disease, warfarin or low molecular weight heparin
  • Subjects in whom the required program of PO and IV fluid hydration is contraindicated, eg, due to pre-existing pulmonary, cardiac, or renal impairment
  • Subjects with known or suspected amyloidosis of any organ
  • Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis
  • Prior exposure to daratumumab
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Listed Location Countries  ICMJE Canada,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01665794
Other Study ID Numbers  ICMJE 12-1088
NCI-2012-01168 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party University of Chicago
Study Sponsor  ICMJE University of Chicago
Collaborators  ICMJE
  • National Cancer Institute (NCI)
  • Multiple Myeloma Research Foundation
Investigators  ICMJE
Principal Investigator: Andrzej Jakubowiak University of Chicago Comprehensive Cancer Center
PRS Account University of Chicago
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP